Rights. Evidence. Transfer.
Most science is never rejected. It is never made evaluable.
Nuclea BioAssets secures the rights to promising life science assets, builds the evidence around them, and prepares them for transfer to the industrial partner able to take them further.
Rights
Commercial rights secured first through options, with title established asset by asset.
Evidence
Narrow validation against success criteria declared before the work begins.
Transfer
A documented package a receiving site can evaluate, reproduce and adopt.
Why we exist
Between a publication and a product, a layer is missing.
Our working hypothesis is that much of the scientific output of Indonesia and the wider ASEAN region stalls for a reason that is neither weak science nor, primarily, scarce capital. An industrial partner is asked to resolve too many unknowns at once, and declines.
- Reproduction outside the originating laboratoryEvidence that the result holds in other hands, at another site.
- A defined product conceptA target product profile that can be written without inventing facts.
- Methods fit for the product classQuality attributes and a justified potency or performance strategy.
- A documented, transferable processCritical parameters on paper, not held in one person's hands.
- A resolved chain of titleWho owns what, who may sign, and on whose authority.
- A preliminary regulatory positionA classification assessment and, where justified, a plan to engage the regulator.
We state this as a hypothesis because it is one. It is tested asset by asset, and our model is designed to find out early if we are wrong.
The ladder
Most arguments about value are arguments about which rung an asset stands on.
A patent grants exclusion. It does not, by itself, establish a product. We take rights at the first two rungs, build the next two, and license or finance at the fifth.
What we mean by an asset
The patent is the smallest part.
In biologics, much of the operative value sits where a patent cannot reach: in the process, the methods, the materials and the people who know how it is actually done. An asset is all of these, held together under rights that allow it to move.
Rights
Patents and applications, exclusive licences and options, field and territory definitions.
Process
Formulations, manufacturing methods, process parameters and transfer protocols.
Methods
Analytical, functional and potency methods that make quality measurable.
Materials
Biological materials, cell banks and cell lines, lawfully obtained and transferable.
Data
Scientific, nonclinical, clinical, manufacturing and regulatory data, with rights of reference.
Know-how
Trade secrets, tacit production knowledge and the continued involvement of the originating team.
Current focus
Regenerative medicine and adjacent biologics: mesenchymal stromal cell derivatives including secretome, conditioned media and extracellular vesicle preparations; tissue-derived biomaterials; cell-based products; and the methods that underpin them. Other fields wait until the first asset is transfer-ready.
A different ownership model
Rights without capability do not travel. Capability without rights has no reason to.
A biological asset loses value when the party that owns it cannot develop it, and the party that can develop it has no stake in where it goes. We hold both, for the same asset, and answer to no counterparty.
Technology transfer offices
Hold the title and the licence terms. Seldom resourced to reproduce, define and package what they own.
Contract research and manufacturing
Can execute to a specification. Work for a fee, and carry no interest in the asset's destination.
Nuclea BioAssets
Controls the rights and directs the translation. Laboratory and manufacturing work is carried out by independently qualified partners against objectives and acceptance criteria we set.
What we are not
- Consultancy
- Patent broker
- Patent warehouse
- CRO
- CDMO
- Clinic
- Facility-first company
The Evidence Pathway
Ten gates. Each one can end the work.
An asset advances only on a decision, taken by a named owner, against evidence defined in advance. Select a gate to see what continues the work and what stops it.
Scouting
A negative but valid result is not repeated to obtain a more favourable answer.Validation rule, gate G4. One repeat is permitted only where the original run is demonstrably technically invalid under criteria set beforehand.
The Technology Transfer Package
What the receiving partner actually receives.
Ten packages, assembled to a repeatable standard. Negative and failed results are included. So are the gaps.
- Legal and IPChain-of-title memorandum, patent family status, freedom-to-operate advice, trade-secret register.
- Scientific evidenceSource data, an independent reproduction report, negative and failed results.
- Product and target profileIndication, population, route, presentation, storage, claim boundaries.
- CMC and manufacturingSource controls, banking strategy, process flow with critical parameters, comparability plan.
- Methods and performanceIdentity, purity, safety testing, characterization, a justified potency or performance strategy.
- Safety, nonclinical and clinicalStatus and gaps, human experience with limitations stated, development plan.
- Regulatory pathwayPreliminary classification, gap analysis, record of any regulator engagement.
- Technology transfer protocolTransfer plan, acceptance criteria, training, person-in-plant provisions.
- Commercial and valuationAddressable market with stated source, adoption barriers, cost to next milestone.
- Risk register and data roomScored risks with owners. An indexed, permissioned, access-logged record.
Structure and capital
Options before ownership. One asset, one company.
Biological assets fail for asset-specific reasons. The structure should let one fail without taking the others with it, and let capital choose the risk it understands.
Staged rights
We begin with an option to license and sponsored validation. Value reaches inventors and institutions as the asset proves itself: milestones, royalties and equity in the company formed around it.
The AssetCo
A qualified asset is developed in its own single-asset company, with its own investors, plan and stopping criteria. It is formed only when rights are sufficiently controlled and the evidence supports it.
Capital discipline
We own no laboratory, plant or clinic. Funding is released against milestones. Timing of any licensing transaction is treated as a planning hypothesis, never as a forecast.
Partners
Four sides of the table. We have written down the objection each should raise.
Terms described here are the structures we propose. Each is settled asset by asset, subject to institutional policy, applicable law and diligence.
What this could become
A standard the region's science can be held to, and carried by.
If the hypothesis holds, the result is larger than any single asset: a repeatable way to move regenerative science from Indonesian and ASEAN laboratories into industrial hands, with the rights clean, the evidence independent and the originators still at the table.
We make science adoptable.
Contact
Tell us which side of the table you sit on.
A first conversation needs no confidential detail. If your asset is unpublished, say only that. We will arrange a non-disclosure agreement before anything is shared.
Jl. KH Mas Mansyur Kav 126
Jakarta Pusat 10250